Roche to increase its payroll in Switzerland by 1.2 percent

Basel, 03 December 2018

Roche is increasing the payroll for its workforce of around 14,000 employees in Switzerland by 1.2% with effect from 1 April 2019. This latest increase acknowledges the great commitment of our employees, taking into account the company's positive performance in a challenging market environment in Europe and Switzerland. The increase also reflects the development of the cost of living.

Over the last few weeks, the Roche Employees Association (AVR) and the Roche Basel Works Council (AKR) held intense negotiations regarding the adjustment of the 2019 payroll. The outcome presented here was achieved with the agreement of the AVR. Unfortunately, an agreement with the AKR could not be reached. The involved parties emphasize that the negotiations took place in a spirit of commitment, fairness and constructiveness.

The 1.2% payroll increase will be used to calculate the total amount available to managers for distribution to their staff in the form of individual, performance-based salary increases as of 1 April 2019.

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit

All trademarks used or mentioned in this release are protected by law.